BACKGROUND: Prostate cancer in men has a high mortality and morbidity due to metastatic disease. The pathobiology of prostate cancer metastasis is not well understood and cell lines and animal models that recapitulate the complex nature of the disease are needed. Therefore, the goal of the study was to establish and characterize a new prostate cancer line derived from a dog with spontaneous prostate cancer. METHODS: A new cell line (Leo) was derived from a dog with spontaneous prostate cancer. Immunohistochemistry and PCR were used to characterize the primary prostate cancer and xenografts in nude mice. Subcutaneous tumor growth and metastases in nude mice were evaluated by bioluminescent imaging, radiography and histopathology. In vitro chemosensitivity of Leo cells to therapeutic agents was measured. RESULTS: Leo cells expressed the secretory epithelial cytokeratins (CK)8, 18, and ductal cell marker, CK7. The cell line grew in vitro (over 75 passages) and was tumorigenic in the subcutis of nude mice. Following intracardiac injection, Leo cells metastasized to the brain, spinal cord, bone, and adrenal gland. The incidence of metastases was greatest to the central nervous system (80%) with a lower incidence to bone (20%) and the adrenal glands (16%). In vitro chemosensitivity assays demonstrated that Leo cells were sensitive to Velcade and an HDAC-42 inhibitor with IC(50) concentrations of 1.9 nm and 0.95 µm, respectively. CONCLUSION: The new prostate cancer cell line (Leo) will be a valuable model to investigate the mechanisms of the brain and bone metastases.
BACKGROUND:Prostate cancer in men has a high mortality and morbidity due to metastatic disease. The pathobiology of prostate cancer metastasis is not well understood and cell lines and animal models that recapitulate the complex nature of the disease are needed. Therefore, the goal of the study was to establish and characterize a new prostate cancer line derived from a dog with spontaneous prostate cancer. METHODS: A new cell line (Leo) was derived from a dog with spontaneous prostate cancer. Immunohistochemistry and PCR were used to characterize the primary prostate cancer and xenografts in nude mice. Subcutaneous tumor growth and metastases in nude mice were evaluated by bioluminescent imaging, radiography and histopathology. In vitro chemosensitivity of Leo cells to therapeutic agents was measured. RESULTS: Leo cells expressed the secretory epithelial cytokeratins (CK)8, 18, and ductal cell marker, CK7. The cell line grew in vitro (over 75 passages) and was tumorigenic in the subcutis of nude mice. Following intracardiac injection, Leo cells metastasized to the brain, spinal cord, bone, and adrenal gland. The incidence of metastases was greatest to the central nervous system (80%) with a lower incidence to bone (20%) and the adrenal glands (16%). In vitro chemosensitivity assays demonstrated that Leo cells were sensitive to Velcade and an HDAC-42 inhibitor with IC(50) concentrations of 1.9 nm and 0.95 µm, respectively. CONCLUSION: The new prostate cancer cell line (Leo) will be a valuable model to investigate the mechanisms of the brain and bone metastases.
Authors: Chand Khanna; Kerstin Lindblad-Toh; David Vail; Cheryl London; Philip Bergman; Lisa Barber; Matthew Breen; Barbara Kitchell; Elizabeth McNeil; Jaime F Modiano; Steven Niemi; Kenine E Comstock; Elaine Ostrander; Susan Westmoreland; Stephen Withrow Journal: Nat Biotechnol Date: 2006-09 Impact factor: 54.908
Authors: Thattawan Kaewsakhorn; William C Kisseberth; Charles C Capen; Kathleen A Hayes; Martin J Calverley; Nongnuch Inpanbutr Journal: Anticancer Res Date: 2005 Jul-Aug Impact factor: 2.480
Authors: M Breen; S Jouquand; C Renier; C S Mellersh; C Hitte; N G Holmes; A Chéron; N Suter; F Vignaux; A E Bristow; C Priat; E McCann; C André; S Boundy; P Gitsham; R Thomas; W L Bridge; H F Spriggs; E J Ryder; A Curson; J Sampson; E A Ostrander; M M Binns; F Galibert Journal: Genome Res Date: 2001-10 Impact factor: 9.043
Authors: Chen-Li Lai; René van den Ham; Geert van Leenders; Jaco van der Lugt; Jan A Mol; Erik Teske Journal: Prostate Date: 2008-04-01 Impact factor: 4.104
Authors: Eyal C Attar; Daniel J De Angelo; Jeffrey G Supko; Ferdinando D'Amato; David Zahrieh; Andres Sirulnik; Martha Wadleigh; Karen K Ballen; Steve McAfee; Kenneth B Miller; James Levine; Ilene Galinsky; Elizabeth G Trehu; David Schenkein; Donna Neuberg; Richard M Stone; Philip C Amrein Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Jessica K Simmons; Wessel P Dirksen; Blake E Hildreth; Carlee Dorr; Christina Williams; Rachael Thomas; Matthew Breen; Ramiro E Toribio; Thomas J Rosol Journal: Prostate Date: 2014-07-07 Impact factor: 4.104
Authors: Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman Journal: Prostate Date: 2014-01-21 Impact factor: 4.104
Authors: Said M Elshafae; Wessel P Dirksen; Aylin Alasonyalilar-Demirer; Justin Breitbach; Shiyu Yuan; Noriko Kantake; Wachiraphan Supsavhad; Bardes B Hassan; Zayed Attia; Lucas B Alstadt; Thomas J Rosol Journal: Prostate Date: 2020-04-29 Impact factor: 4.104
Authors: J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol Journal: Vet Pathol Date: 2015-05-28 Impact factor: 2.221
Authors: Katharina A Sterenczak; Martin Meier; Silke Glage; Matthias Meyer; Saskia Willenbrock; Patrick Wefstaedt; Martina Dorsch; Jörn Bullerdiek; Hugo Murua Escobar; Hans Hedrich; Ingo Nolte Journal: BMC Cancer Date: 2012-07-11 Impact factor: 4.430